GNBT.OB

[Ares]

Price recently broke the 5 minute upper descending trendline and 1 minute stochastics currently oversold.
Potential double bottom on the 1 minute chart?

[Ares]

On paper, I'm bidding at 1.92 with a stop just below 1.91.

[Ares]

Pivot = 1.94

[Ares]

Here's my most recent building for GNBT:

June 25's Building of GNBT

2.1554

2.14

2.0959
2.05

1.999765
1.98506

1.965
1.965
1.94494

1.94

1.930235
1.89
1.88                        

1.8341                        

1.7746
                        
1.52004   1.8562   1.96004   2.06388   2.14   2.40004   2.63764   2.94564   (Extension using high of 2.14,low of 1.26, and a retracement of 1.52)

1.26                        

[Ares]

Will the blue "container" protect price?
Recent Price/Volume relationship on the daily chart:
Volume up while price went up
Volume down when price went down.

Will a 1.27 retracement of 1.78 be used in confluence with the daily 8 ema or
will a 1.62 retracement be used of 1.73 to coincide with the uptrend/downtrend junction?

We will have to find out what the market decides to do.

Note: We have to remember that the support and resistance areas are not guarantees but expectations.

[Ares]

GNBT active at premarket.
The support/resistance are just gauges.
If there's a short squeeze...

[Ares]

1.618 of the 5 minute opening range is 1.77.
If I bid at 1.77 would i still get exceuted?
Green at 1.79.
Let's say I buy at the ask of 1.79 with a mental stop of 1.69 what would happen.

[Ares]

Price and Volume relationship of the 5 minute chart.
So far, what i see is price decreasing as price is decreasing.
Will we get an R2R (not good)
or R2B which may turn to B2B.

[tokyopua]

Looks like a 3 year symetrical triangle forming on GNBT.  I have it on watch, might be nice to buy around the 1.3x range...

[Draak]

Way oversold. Technically worth a break out. With news far higher.

[Draak]

October 9, 2007 - 8:41 AM EST           

Generex Biotechnology RNAi-Based Tumor Vaccine Set for Trials in China to be Presented At Leading International Oncology Meeting
WORCESTER, Mass., Oct. 9, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) announced today that Dr. Minzhen Xu, Vice President of Biology at Antigen Express, Inc., the Company's immunotherapy subsidiary, will make a presentation at a scientific symposium on the Company's strategy for converting cancer cells into potent tumor vaccine cells

Dr. Xu will present "Inhibition of MHC class II-associated Invariant Chain Generates Potent Tumor Cell Vaccine" at the 12th World Congress on Advances in Oncology to be held at the Creta Maris Hotel, Hersonissos, Crete, Greece, to be held from Oct. 11 through the 13th. The conference will focus on a variety of aspects of tumor biology and therapeutics. Dr. Xu will co-Chair and present in the Experimental Therapeutics/Vaccines section on Oct. 13th.

The talk by Dr. Xu will present pre-clinical studies that Antigen Express has performed in preparation for clinical trials in China. Robust anti-tumor immunity has been demonstrated in a variety of mouse tumor models as well as safety using the RNAi approached developed at Antigen Express. The trials in China will be performed in collaboration with Dr. Daopei Lu and the Beijing Daopei Hospital in Beijing, China. Dr. Lu is a world-renowned hematologist-oncologist who has conducted many clinical trials and has authored over 200 articles in peer-review journals.

The strategy being developed by Antigen Express is to force tumor cells to express tumor associated antigens in a way that that makes them more visible to the immune system. This is done by suppressing expression of the MHC class II-associated invariant chain in tumor cells using RNAi. MHC class II molecules are naturally expressed in many cells of the body including some types of cancer cells. The invariant chain prevents class II molecules from associating with antigenic peptides in the cytoplasm of cells (where tumor associated antigens are found) and presenting them for recognition by T helper cells. Antigen-specific stimulation of T helper cells is pivotal in allowing the immune system to recognize novel pathogenic agents. While a number of groups have demonstrated the efficacy of this strategy in pre-clinical models, Antigen Express has developed proprietary methods using RNAi that make this approach feasible in the clinic.

Antigen Express is focused on developing active immunotherapy products for serious diseases and unmet medical needs. Currently the company has an immunotherapeutic peptide in Phase II clinical trials for breast cancer and in Phase I trials for the potentially pandemic H5N1 avian influenza.

[Draak]

Lot of upside to overbought. Breakout?

[firefoxfromitaly]

just in @ 1.69

any toughts ??

[setravis]

REPORTS APPROVAL FROM UAE MINISTRY: Generex Biotechnology Corporation (GNBT)
announced that the Ministry of Health of the United Arab Emirates, Drugs Control Department
has issued a non-objection letter to the Imperial College London Diabetes Centre to import
Generex Oral-lyn(TM), Generex's proprietary oral insulin spray product, into Abu Dhabi. The
Manager of the Drugs Control Department indicated that importation of Generex Oral-lyn can be
done via the issuance of a purchase order from the Imperial College London Diabetes Centre to
a drug store or pharmacy licensed by the Ministry of Health of the United Arab Emirates. According
to the International Diabetes Federation the UAE has the second highest rate of diabetes in
the world, affecting 20% of residents. Abu Dhabi is the capital and second largest city of the UAE
with a population of 2.3 million. It is also geographically the largest of the seven emirates.

[JohnDoe]

Please see below an GNBT updated chart.
I hope that the uptrend already started.

Have nice trades!!

John Doe